Abstract:Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Despite improved remission rates, current treatment regimens for AML are often associated with a very poor prognosis and adverse effects, necessitating more effective and safer agents. B-cell leukemia/lymphoma 2 (Bcl-2) family proteins regulate apoptotic pathway that can be targeted with small molecule inhibitors. APG-1252-12A is a Bcl-2 homology (BH)-3 mimetic that specifically binds to Bcl-2 and Bcl-xl, which has shown efficacy in some Bcl-2 dependent hematological cancers. In this study, we investigated whether APG-1252-12A inhibits the growth of five leukemia cell lines in a concentration- or time-dependent manner by MTS assay. Following treatment of AML cell line HL-60 with this compound, cell apoptosis was detected using flow cytometry and nuclear condensation was observed after Hoechst 33258 dye. Immunoblotting for cytochrome c, cleaved caspase-3 and PARP-1 cleavage was used to demonstrate the mechanism of inducing mitochondria-dependent apoptosis by APG-1252-12A. Our findings showed that this new compound inhibited cell proliferation in five leukemia cell lines and induced apoptotic death. There was a link between the level of Bcl-2 protein and IC50. APG-1252-12A targeted mitochondria and induced caspase-dependent apoptosis by inducing the HL-60 cell cytochrome c released, PARP cleavage and caspase activation. These data suggested that APG-1252-12A is a candidate drug for the in vivo analysis and clinical evaluation in AML.

Discovery of novel selective phosphodiesterase‐1 inhibitors for the treatment of acute myelogenous leukemia

A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells

Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia

Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia

Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Design and Optimization of Selective and Potent CDK9 Inhibitors with Flavonoid Scaffold for the Treatment of Acute Myeloid Leukemia.

Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives As Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Targeting PDK1 with dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell growth

Discovery of novel pyrrolo[2,3- d ]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors

Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1H-Pyrazole-3-Carboxamide Derivatives and Their Potent Activity Against Acute Myeloid Leukemia (AML)

Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells

Discovery of a Novel Oral Type Ⅰ CDK8 Inhibitor Against Acute Myeloid Leukemia.

Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia

Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia

A Pyridinesulfonamide Derivative FD268 Suppresses Cell Proliferation and Induces Apoptosis Via Inhibiting PI3K Pathway in Acute Myeloid Leukemia

Discovery of Phenylpyrazole Derivatives As a New Class of Selective Inhibitors of MCL-1 with Antitumor Activity

Discovery of a High Potent PIM Kinase Inhibitor for Acute Myeloid Leukemia Based on N-pyridinyl Amide Scaffold by Optimizing the Fragments Toward to Lys67 and Asp128/Glu171.

APG-1252-12A Induces Mitochondria-Dependent Apoptosis Through Inhibiting the Antiapoptotic Proteins Bcl-2/Bcl-xl in HL-60 Cells

Synthesis and Biological Evaluation of Dithiocarbamate Esters of Parthenolide As Potential Anti-Acute Myelogenous Leukaemia Agents.

Discovery of a selective YTHDC1 inhibitor that targets acute myeloid leukemia